Grand Pharmaceutical Group Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Grand Pharmaceutical Group kazanç ve gelirin sırasıyla yıllık 3.1% ve 8.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 2.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 13.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

3.1%

Kazanç büyüme oranı

2.65%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	10.8%
Gelir büyüme oranı	8.7%
Gelecekteki özkaynak getirisi	13.50%
Analist kapsamı	Low
Son güncelleme	13 May 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

Grand Pharmaceutical Group Limited (HKG:512) Stock Rockets 41% As Investors Are Less Pessimistic Than Expected

May 12

Grand Pharmaceutical Group Limited's (HKG:512) CEO Compensation Looks Acceptable To Us And Here's Why

Apr 03

Additional Considerations Required While Assessing Grand Pharmaceutical Group's (HKG:512) Strong Earnings

Mar 25

Little Excitement Around Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Feb 24

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 19

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Jun 05

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

May 22

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25

Kazanç ve Gelir Büyüme Tahminleri

SEHK:512 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (HKD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	15,008	2,797	2,085	2,810	1
12/31/2026	13,902	2,350	1,252	2,377	4
12/31/2025	12,222	2,175	1,466	2,325	3
12/31/2024	11,645	2,468	1,301	1,898	N/A
9/30/2024	11,116	2,438	1,376	1,900	N/A
6/30/2024	10,587	2,409	1,451	1,903	N/A
3/31/2024	10,558	2,144	1,694	2,164	N/A
12/31/2023	10,530	1,880	1,937	2,425	N/A
9/30/2023	10,434	2,139	1,349	2,114	N/A
6/30/2023	10,339	2,398	761	1,804	N/A
3/31/2023	9,951	2,239	773	1,823	N/A
12/31/2022	9,562	2,079	785	1,843	N/A
9/30/2022	9,403	1,995	1,068	1,829	N/A
6/30/2022	9,244	1,910	1,350	1,815	N/A
3/31/2022	8,921	2,156	1,410	1,911	N/A
12/31/2021	8,598	2,403	1,469	2,006	N/A
9/30/2021	8,131	2,340	1,487	2,001	N/A
6/30/2021	7,664	2,277	1,504	1,995	N/A
3/31/2021	7,008	2,035	1,351	1,726	N/A
12/31/2020	6,353	1,793	1,197	1,456	N/A
9/30/2020	6,306	1,558	1,020	1,400	N/A
6/30/2020	6,259	1,323	843	1,345	N/A
3/31/2020	6,425	1,237	790	1,324	N/A
12/31/2019	6,591	1,151	737	1,304	N/A
9/30/2019	6,450	1,048	1,177	1,661	N/A
6/30/2019	6,309	944	1,618	2,017	N/A
3/31/2019	6,134	828	1,326	1,713	N/A
12/31/2018	5,958	713	1,034	1,408	N/A
9/30/2018	5,845	642	N/A	898	N/A
6/30/2018	5,732	570	N/A	387	N/A
3/31/2018	5,251	516	N/A	553	N/A
12/31/2017	4,771	461	N/A	720	N/A
9/30/2017	4,480	413	N/A	708	N/A
6/30/2017	4,190	364	N/A	696	N/A
3/31/2017	3,943	317	N/A	736	N/A
12/31/2016	3,696	269	N/A	775	N/A
9/30/2016	3,573	241	N/A	807	N/A
6/30/2016	3,450	213	N/A	839	N/A
3/31/2016	3,348	197	N/A	668	N/A
12/31/2015	3,246	181	N/A	496	N/A
9/30/2015	3,158	187	N/A	439	N/A
6/30/2015	3,071	194	N/A	382	N/A
3/31/2015	3,097	185	N/A	430	N/A
12/31/2014	3,122	175	N/A	477	N/A
9/30/2014	3,040	150	N/A	602	N/A
6/30/2014	2,958	126	N/A	728	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 512 'nin tahmini kazanç büyümesi (yıllık 3.1% ) tasarruf oranının ( 2.4% ) üzerindedir.

Kazançlar ve Piyasa: 512 şirketinin kazançlarının (yıllık 3.1% ) Hong Kong pazarından (yıllık 10.4% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 512 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 512 şirketinin gelirinin (yıllık 8.7% ) Hong Kong pazarından (yıllık 8.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 512 şirketinin gelirinin (yıllık 8.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 512 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 13.5 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/17 01:07
Gün Sonu Hisse Fiyatı	2025/05/16 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Grand Pharmaceutical Group Limited 6 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Yanyin Zhu	China International Capital Corporation Limited
Xiao Wei Lin	Everbright Securities Co. Ltd.
Chao Zhang	Guosen Securities Co., Ltd.

Grand Pharmaceutical Group Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 11% to HK$8.03

Price target increased by 9.1% to HK$7.23

Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Recent updates

Executive Chairman recently bought HK$398k worth of stock

Price target increased by 11% to HK$8.03

Grand Pharmaceutical Group Limited (HKG:512) Stock Rockets 41% As Investors Are Less Pessimistic Than Expected

Grand Pharmaceutical Group Limited Announces Phase III Study in China of the Group's Global Innovative RDC TLX591-CDx Completes Patient Enrollment and Dosing to Be Submitted This Year

Grand Pharma's Global Innovative Product STC3141 Successfully Reached the Clinical Endpoint in the Phase II Clinical Study in China

Investor sentiment improves as stock rises 19%

The Group's First Generic Fluticasone Propionate Nasal Spray in China Approved for Commercialization

Grand Pharmaceutical Group Limited Announces the Investigator-Initiated Clinical Study Conducted in China of GPN02006

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2024

Upcoming dividend of HK$0.26 per share

Grand Pharmaceutical Group Limited's (HKG:512) CEO Compensation Looks Acceptable To Us And Here's Why

Executive Chairman recently bought HK$413k worth of stock

Additional Considerations Required While Assessing Grand Pharmaceutical Group's (HKG:512) Strong Earnings

Grand Pharmaceutical Group Limited Completes First Patient Enrolment and Dosing for International Multi-Center Phase III Clinical Trial in China of the Innovative RDC Product ITM-11

Price target increased by 9.1% to HK$7.23

Grand Pharmaceutical Group Limited, Annual General Meeting, Apr 10, 2025

Full year 2024 earnings: EPS exceeds analyst expectations

Grand Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2024, Payable on 30 April 2025

Grand Pharmaceutical Group Limited to Report Fiscal Year 2024 Results on Mar 12, 2025

Little Excitement Around Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China

Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China

Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA

National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11

Investor sentiment improves as stock rises 15%

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024

Grand Pharmaceutical Group Limited Announces Executive Changes

Executive Chairman recently bought HK$526k worth of stock

Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.26 per share

Executive Chairman recently bought HK$271k worth of stock

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Executive Chairman recently bought HK$489k worth of stock

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Executive Chairman recently bought HK$371k worth of stock

Executive Chairman recently bought HK$243k worth of stock

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Dividend increased to HK$0.26

Executive Chairman recently bought HK$381k worth of stock

Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Full year 2023 earnings: EPS misses analyst expectations

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002)

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint

Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate

Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023

Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director

Less than half of directors are independent

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Grand Pharmaceutical Group Limited Announces Board Changes

Upcoming dividend of HK$0.14 per share at 2.9% yield

Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?